Current Neuropharmacology
Title:ERRATUM
Volume: 10 Issue: 2
Export Options
About this article
Cite this article as:
ERRATUM, Current Neuropharmacology 2012; 10 (2) . https://dx.doi.org/10.2174/157015912800604524
DOI https://dx.doi.org/10.2174/157015912800604524 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
36
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Stingless Bee Honey Reduces Anxiety and Improves Memory of the Metabolic Disease-induced Rats
CNS & Neurological Disorders - Drug Targets Overcoming Barriers to Evidence-Based Diabetes Care
Current Diabetes Reviews Paranoigenic Extremes - a Reappraisal Concerning Paranoid Personality Disorder
Current Psychiatry Reviews Inflammatory Process in Parkinsons Disease: Role for Cytokines
Current Pharmaceutical Design Dissecting the Diverse Actions of Pro- and Mature Neurotrophins
Current Alzheimer Research Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Message from the Editor-in-Chief
CNS & Neurological Disorders - Drug Targets Enhancing Yeast Transcription Analysis Through Integration of Heterogeneous Data
Current Genomics Drug Withdrawal and Hyperphagia: Lessons from Tobacco and Other Drugs
Current Pharmaceutical Design Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry Design, Synthesis and Evaluation of Dual-targeting Prodrug Co-modified by Organic Amine and L-ascorbic Acid for CNS Delivery
Letters in Drug Design & Discovery Excess Exposure to Insulin Is the Primary Cause of Insulin Resistance and its Associated Atherosclerosis
Current Molecular Pharmacology Potassium Channels and CNS Diseases
CNS & Neurological Disorders - Drug Targets Endocrine Therapies and QTc Prolongation
Current Drug Safety A Glycemic Threshold of 90 mg/dl Promotes Early Signs of Atherosclerosis in Apparetly Healthy Overweight/Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants
Current Neuropharmacology The Matrix Metalloproteinases Panel in Multiple Sclerosis Patients Treated with Natalizumab: A Possible Answer to Natalizumab Non- Responders
CNS & Neurological Disorders - Drug Targets Green Tea from the Far East to the Drug Store: Focus on the Beneficial Cardiovascular Effects
Current Pharmaceutical Design The Glycogen Synthase Kinase-3 in the Regulation of Ion Channels and Cellular Carriers
Current Medicinal Chemistry Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication
Current Alzheimer Research